Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

NCT05217927 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05217927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05217927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
March 4, 2022
Completion date
December 11, 2024
Enrollment
1,415 (actual)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

migraine